Price Alert

Arcellx Inc. (ACLX)

NASDAQ: ACLX · Real-Time Price · USD

72.62

0.46 (0.64%)

At close: Sep 05, 2025, 3:59 PM

72.62

0.00%

After-hours: Sep 05, 2025, 05:34 PM EDT

0.64% (1D)

Bid	70.32
Market Cap	4.03B
Revenue (ttm)	56.98M
Net Income (ttm)	-187.99M
EPS (ttm)	-3.41
PE Ratio (ttm)	-21.3
Forward PE	-21.87
Analyst	Buy

Ask	75
Volume	328,705
Avg. Volume (20D)	581,798.7
Open	72.06
Previous Close	72.16
Day's Range	70.78 - 73.10
52-Week Range	47.86 - 107.37
Beta	0.27

About ACLX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ACLX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ACLX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Arcellx Inc. is scheduled to release its earnings on Nov 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

10 months ago

+0.79%

Acrellx shares are trading lower after the company... Unlock content with Pro Subscription

News

3 days ago · businesswire.com

Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...

4 weeks ago · seekingalpha.com

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...

1 month ago · zacks.com

Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $0.51 per share a year ago.

1 month ago · fool.com

Arcellx (ACLX) Q2 Revenue Drops 72%

1 month ago · seekingalpha.com

Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market

Arcellx, Inc. is advancing its lead CAR-T therapy, anito-cel, for relapsed/refractory multiple myeloma, with the pivotal phase 3 iMMagine-3 trial underway. Recent positive phase 2 iMMagine-1 data supp...